Related Experiment Video

Updated: Aug 15, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Size limits of thiocarbamides accepted as substrates by human flavin-containing monooxygenase 1

Y M Kim1, D M Ziegler

  • 1Department of Chemistry and Biochemistry, The University of Texas, Austin, Texas, USA.

Drug Metabolism and Disposition: the Biological Fate of Chemicals
|July 20, 2000
PubMed

Insights

Human flavin-containing monooxygenase 1 (FMO1) in insect cells oxidizes methimazole and related compounds. Its substrate specificity is restricted, excluding larger molecules and differing from FMO1 in other species.

Area of Science:

  • Biochemistry
  • Enzymology
  • Pharmacology

Background:

  • Flavin-containing monooxygenase 1 (FMO1) is a key enzyme in xenobiotic metabolism.
  • Understanding FMO1 substrate specificity is crucial for drug development and toxicity assessment.
  • Insect cell-based expression systems are valuable tools for studying human enzymes.

Purpose of the Study:

  • To characterize the substrate specificity of human FMO1 using a recombinant baculovirus expression system.
  • To investigate the catalytic activity of human FMO1 towards various thiocarbamides and amines.
  • To compare the substrate preference of human FMO1 with FMO1 from other species.

Main Methods:

  • Microsomes were isolated from Spodoptera frugiperda (Sf)9 cells infected with human FMO1 recombinant baculovirus.
  • Enzyme kinetics were determined by measuring NADPH- and O2-dependent oxidation of methimazole.
  • Inhibition studies were performed using various amines as potential alternative substrates.

Main Results:

  • Human FMO1 catalyzed the oxidation of methimazole, thiourea, and phenylthiourea.
  • Activity was not detected with 1,3-diphenylthiourea or larger thiocarbamides, indicating size limitations.
  • N,N-dimethylaniline and chlorpromazine inhibited methimazole oxidation, suggesting they are alternate substrates.
  • Human FMO1 exhibited a more restricted substrate specificity compared to pig or guinea pig FMO1.

Conclusions:

  • Human FMO1 possesses a defined substrate-binding pocket with size constraints for xenobiotics.
  • The substrate specificity of human FMO1 is significantly narrower than that observed in other species.
  • Extrapolation of structure-activity relationship data from animal models to human FMO1 requires careful consideration of species-specific differences.

More Related Videos

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors10:28

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors

Published on: August 17, 2019

High-Resolution Fluorespirometry to Assess Dynamic Changes in Mitochondrial Membrane Potential in Human Immune Cells07:18

High-Resolution Fluorespirometry to Assess Dynamic Changes in Mitochondrial Membrane Potential in Human Immune Cells

Published on: May 24, 2024

Related Concept Videos

Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...